department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Jemperli · pharmadog

pharmadog
drugs
Jemperli

drug · antibody

patient view →

dostarlimab

Phase 2updated 2mo ago

by $GSK GSK plc🔗 ChEMBL

Phase 2

community read0 votes

Antibody drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 16 investigational indications.

indications

indications

NSCLCColorectal Cancer

targets

Programmed cell death protein 1

all catalysts(1)

phase 2 initiation · 1

News(0)

no news has mentioned this drug yet

brand

Jemperli

trade names

Jemperli

generic

dostarlimab-gxly

MOA

Programmed cell death protein 1 antagonist

indication

Rectal Cancer

phase

phase_2

phase 2 initiation

GSK plc — dostarlimab (Phase II Trial Initiation)

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 2h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

$GSK53.66+4.60%

🐶 often sniffed alongside

top 3

company$GSKGSK plc1 co-mentions · 1 sources
company$GLAXFGSK plc1 co-mentions · 1 sources
tagInfectious Disease1 co-mentions · 1 sources

Trials studying dostarlimab

phase3Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapyactive not recruitingn=758
phase2A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Canceractive not recruitingn=351
phase1Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancerrecruitingn=21
phase2Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinomaactive not recruitingn=34
phase2Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumorsrecruitingn=212
phase2Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCCcompletedn=10
phase2A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202active not recruitingn=316
phase2A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancerrecruitingn=120

more trials →